Valuation: Hologic, Inc.

Capitalization 16.97B 14.54B 13.29B 12.59B 23.3B 1,622B 23.49B 159B 61.62B 771B 63.68B 62.32B 2,684B P/E ratio 2024
24.3x
P/E ratio 2025 27x
Enterprise value 17.39B 14.9B 13.62B 12.9B 23.88B 1,663B 24.07B 163B 63.14B 790B 65.26B 63.87B 2,750B EV / Sales 2024
4.74x
EV / Sales 2025 3.75x
Free-Float
73.08%
Yield 2024 *
-
Yield 2025 -
1 day+0.48%
3 months+1.29%
6 months+2.51%
Current year+2.04%
Current year 74.49
Extreme 74.49
76.07
1 year 53.62
Extreme 53.62
76.07
3 years 51.9
Extreme 51.9
84.67
5 years 51.9
Extreme 51.9
87.88
10 years 26.49
Extreme 26.49
87.88
Manager TitleAgeSince
Chief Executive Officer 63 07/04/2026
Director of Finance/CFO - 16/04/2026
Chief Operating Officer 46 01/01/2024
Director TitleAgeSince
Director/Board Member 63 07/04/2026
Change 5d. change 1-year change 3-years change Capi.($)
+0.48%-.--%+37.30%-8.17% 16.97B
+0.49%-5.53%+10.38%-14.57% 167B
-0.97%-5.61%-24.36%+40.22% 152B
-0.87%-6.33%-12.39%-27.62% 116B
+0.92%-5.34%-47.98%+0.39% 79.59B
-0.06%-1.72%+5.98%-8.79% 46.84B
-1.13%+0.48%-30.81%-38.32% 44.42B
-0.51%-4.93%-3.52%+22.96% 32.72B
+0.46%-4.54%+1.56%-11.16% 32.01B
-2.83%-5.43%-30.47%-47.44% 28.74B
Average -0.40%-3.73%-9.43%-9.25% 71.59B
Weighted average by Cap. -0.31%-4.63%-12.05%-3.82%

Financials

2024 2025
Net sales 4.03B 3.45B 3.16B 2.99B 5.53B 385B 5.58B 37.68B 14.63B 183B 15.12B 14.8B 637B 4.1B 3.51B 3.21B 3.04B 5.63B 392B 5.68B 38.33B 14.89B 186B 15.39B 15.06B 648B
Net income 790M 676M 618M 586M 1.08B 75.49B 1.09B 7.38B 2.87B 35.87B 2.96B 2.9B 125B 566M 485M 443M 420M 777M 54.09B 783M 5.29B 2.05B 25.7B 2.12B 2.08B 89.46B
Net Debt 321M 275M 252M 238M 441M 30.72B 445M 3B 1.17B 14.6B 1.21B 1.18B 50.81B 421M 361M 330M 312M 578M 40.24B 583M 3.93B 1.53B 19.12B 1.58B 1.55B 66.56B
Logo Hologic, Inc.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - breast health (36.2%): digital mammography and breast biopsy solutions and systems; - molecular diagnostics (31.9%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - gynecological surgery (16.6%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - cytology and perinatal diagnostics (11.9%); - bone health (2.7%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment; - blood screening (0.7%). Net sales break down by source of revenue between sales of products (79.4%) and services (20.6%). Net sales are distributed geographically as follows: the United States (74.3%), Europe (14.4%), Asia/Pacific (6%) and other (5.3%).
Employees
7,070
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA